Imaging and therapy of hSSTR2-transfected tumors using radiolabeled somatostatin analogs
详细信息 查看全文
- 作者：Zhe Wang (1)
Wenhui Ma (1)
Jing Wang (1)
Jinglan Deng (1)
Menghui Yuan (1)
Mingxuan Zhao (1)
Lintao Jia (2)
Weidong Yang (1)
Rui Zhang (2)
Weiwei Qin (2)
Dake Chu (3)
Guoquan Li (1) - 关键词：Somatostatin ; Receptor imaging ; Lung cancer ; Gene therapy
- 刊名：Tumor Biology
- 出版年：2013
- 出版时间：August 2013
- 年：2013
- 卷：34
- 期：4
- 页码：2451-2457
- 全文大小：485KB
- 参考文献：1. Gambhir SS, Herschman HR, Cherry SR, et al. Imaging transgene expression with radionuclide imaging technologies. Neoplasia. 2000;2:118-8. CrossRef
2. Arne G, Nilsson B, Dalmo J, et al. Gastrointestinal stromal tumors (GISTs) express somatostatin receptors and bind radiolabeled somatostatin analogs. Acta Oncol. 2013;52(4):783-2. doi:10.3109/0284186X.2012.733075 . CrossRef
3. De K, Bhowmik A, Behera A, Banerjee I, Ghosh MK, Misra M. Synthesis, radiolabeling, and preclinical evaluation of a new octreotide analog for somatostatin receptor-positive tumor scintigraphy. J Pept Sci. 2012. doi:10.1002/psc.2458 .
4. Erfani M, Shafiei M, Mazidi M, Goudarzi M. Preparation and biological evaluation of [99mTc/EDDA/Tricine/HYNIC0,BzThi3]-octreotide for somatostatin receptor-positive tumor imaging. Cancer Biother Radiopharm. 2013. doi:10.1089/cbr.2012.1270 .
5. Florio T, Montella L, Corsaro A, et al. In vitro and in vivo expression of somatostatin receptors in intermediate and malignant soft tissue tumors. Anticancer Res. 2003;23:2465-1.
6. Lamberts SW, de Herder WW, Hofland LJ. Somatostatin analogs in the diagnosis and treatment of cancer. Trends Endocrinol Metab. 2002;13:451-. CrossRef
7. Kailey B, van de Bunt M, Cheley S, et al. SSTR2 is the functionally dominant somatostatin receptor in human pancreatic beta- and alpha-cells. Am J Physiol Endocrinol Metab. 2012;303:E1107-6. CrossRef
8. Richard JC, Factor P, Welch LC, Schuster DP. Imaging the spatial distribution of transgene expression in the lungs with positron emission tomography. Gene Ther. 2003;10:2074-0. CrossRef
9. Thakur M, Kolan H, Rifat S, et al. Vapreotide labeled with Tc-99m for imaging tumors. Int J Oncol. 1996;9:445-1.
10. Tsai C, Leslie JS, Franko-Tobin LG, et al. Valproic acid suppresses cervical cancer tumor progression possibly via activating Notch1 signaling and enhances receptor-targeted cancer chemotherapeutic via activating somatostatin receptor type II. Arch Gynecol Obstet. 2013. doi:10.1007/s00404-013-2762-7 .
11. Demiroglu H, Avcibasi U, Unak P, et al. Radiolabeling of bleomycin-glucuronide with (131)I and biodistribution studies using xenograft model of human colon tumor in Balb/C mice. Cancer Biother Radiopharm. 2012;27:371-3. CrossRef
12. Hofland LJ, van Koetsveld PM, Waaijers M, Zuyderwijk J, Breeman WA, Lamberts SW. Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide. Endocrinology. 1995;136:3698-06. CrossRef
13. Pruszynski M, Koumarianou E, Vaidyanathan G, et al. Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody. Nucl Med Biol. 2013;40:52-. CrossRef
14. Ma W, Kang F, Wang Z, et al. 99mTc-labeled monomeric and dimeric NGR peptides for SPECT imaging of CD13 receptor in tumor-bearing mice. Amino Acids. 2013. doi:10.1007/s00726-013-1469-1 .
15. Cheng C, Pan L, Dimitrakopoulou-Strauss A, Strauss LG. A new approach for the development of tracers: data base screening and in silico modeling for the identification of new ligands for SSTR2. Hell J Nucl Med. 2008;11:101-.
16. Yue JT, Riddell MC, Burdett E, Coy DH, Efendic S, Vranic M. Amelioration of hypoglycemia via somatostatin receptor type 2 antagonism in recurrently hypoglycemic diabetic rats. Diabetes. 2013. doi:10.2337/db12-1523 .
17. Matrone C, Pivonello R, Colao A, et al. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs. Neuroendocrinology. 2004;79:142-. CrossRef
18. Papotti M, Bongiovanni M, Volante M, et al. Expression of somatostatin receptor types 1- in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch. 2002;440:461-5. CrossRef
19. Nguyen K, Parry JJ, Rogers BE, Anderson CJ. Evaluation of copper-64-labeled somatostatin agonists and antagonist in SSTr2-transfected cell lines that are positive and negative for p53: implications for cancer therapy. Nucl Med Biol. 2012;39:187-7. CrossRef
20. Sclafani F, Carnaghi C, Di Tommaso L, et al. Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumors. Tumori. 2011;97:620-.
21. Winnard Jr P, Virzi E, Fogarasi M, Rusckowski M, Hnatowich DJ. Investigations of directly labeling antibodies with rhenium-188. Q J Nucl Med. 1996;40:151-0. - 作者单位：Zhe Wang (1)
Wenhui Ma (1)
Jing Wang (1)
Jinglan Deng (1)
Menghui Yuan (1)
Mingxuan Zhao (1)
Lintao Jia (2)
Weidong Yang (1)
Rui Zhang (2)
Weiwei Qin (2)
Dake Chu (3)
Guoquan Li (1)
1. Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi Province, China
2. Department of Biochemical and Molecular biology, Fourth Military Medical University, Xi’an, Shaanxi Province, China
3. State Key Laboratory of Cancer Biology, Department of Gastrointestinal Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an, Shaanxi Province, China - ISSN：1423-0380
文摘
The aim of this study was to introduce human somatostatin receptors subtype-2 (hsstr2) gene into A549 lung carcinoma cells in order to investigate the role of these receptors, and to observe the lethal effect of 131I-RC-160 (RC-160, vapreotide, an analog of somatostatin) on transfected cells through tumor scintigraphy. Clones overexpressing SSTR2 were selected for radioligand-receptor binding assay and assessment of 125I-RC-160 internalization. The methylthiazolyl tetrazolium test was used to observe the lethal effect of 131I-RC-160, Na131I, and RC-160 on hSSTR2-transfected A549 cells (A549-hSSTR2). Planar imaging was performed with a gamma camera equipped with pinhole collimator in nude mice bearing both A549-hSSTR2 tumors overexpressing SSTR2 and A549-pcDNA3 (pcDNA3-transfected A549 cells) tumors as control. Images were obtained at 0.5, 6, and 24?h after injection of 3.7?×-06?Bq 99mTc-RC-160 via the tail vein. The inhibitory effects of 131I-RC-160, RC-160, and Na131I on the tumors were recorded by measuring the tumor volumes. At the end of the study, the tumors were excised and HE staining was performed. The binding radioactivity (sum of membrane-bound and internalized radioligand) of A549-hSSTR2 cells was 18.24?±-.9?% of total counts added after 1?h of incubation, and was higher than that of A549-pcDNA3 cells 5.7?±-.4?% (P-lt;-.05). The inhibition ratio of A549-hSSTR2 cells was 78.8?±-.9?%. Clear images of tumor lesions in nude mice were achieved at 0.5?h post injection. In the A549-hSSTR2 xenograft tumor group, the growth of the tumors treated with 131I-RC-160 was significantly inhibited as compared to tumors in the group treated with RC-160 (P-lt;-.01). This study demonstrated that it was possible to introduce hsstr2 to non-expressing tumor cell lines and treat tumors with radiolabeled somatostatin analogs.